7:00 AM
 | 
Dec 22, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

FDA lifts hold on Denali PD candidate

Denali Therapeutics Inc. (NASDAQ:DNLI) said FDA lifted a partial clinical hold on a Phase I study of Parkinson's disease candidate DNL201. It is a leucine-rich repeat kinase 2 (LRRK2) inhibitor.

The agency placed the hold to impose an...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >